This Article Abstract Free Full Text (Free PDF) Free Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Macgregor, J. T. Search for Related Content PubMed PubMed Citation Articles by Macgregor, J. T. Pubmed/NCBI databases Medline Plus Health Information Cancer Cancer Chemotherapy Social Bookmarking                         What's this?

Biomarkers of Cancer Risk and Therapeutic Benefit: New Technologies, New Opportunities, and Some Challenges

FDA National Center for Toxicological Research, Rockville, Maryland, USA, jmacgregor{at}nctr.fda.gov

The biotechnology revolution offers unprecedented opportunities for identification of mechanistically-based biomarkers that report and predict cancer and other pathologies. The combination of genomic technologies with a knowledge of gene sequence and sequence conservation has made available markers that facilitate the correlation of genetic variation with biological outcomes, and "-omic" technologies allow efficient biochemical characterization of functional pathways—providing new markers of the susceptibility of individuals to cancer development, and of tumor susceptibility to specific therapies. New therapeutic agents targeted to individuals with specific genetic or biochemical characteristics already exist. The powerful -omic technologies allow efficient monitoring of gene transcripts, proteins, and intermediary metabolites, making it possible to monitor a large number of key cellular pathways simultaneously. This has enabled the identification of key biomarkers and signaling molecules associated with cell growth, cell death, and cellular metabolism. These new markers are facilitating monitoring of functional disturbance, molecular and cellular damage, and damage-response. Improved imaging technologies have made it feasible to image some of these molecular events noninvasively. To meet the challenge of evaluating and developing consensus criteria for the application of these new technologies and biomarkers, consortium approaches are being increasingly undertaken to share resources and to build a common understanding among the research, industry, and regulatory communities. These developments promise more efficient pharmaceutical product development, safer and more efficacious drugs, and provide clinical practitioners with new and better biomarkers for cancer screening, patient monitoring, and choice of therapy.

Key Words: Biomarkers • cancer • susceptibility • toxicity • efficacy • polymorphism.

References

• Aardema, M.J., and MacGregor, J.T. (2002). Toxicology and genetic toxicology in the new era of toxicogenomics: impact of "-omics" technologies. Mutat Res 499, 13—25.[Web of Science][Medline] [Order article via Infotrieve]
• Albertini, R.J. (2001). HPRT mutations in humans: biomarkers for mechanistic studies. Mutat Res 489, 1—16.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Artemov, D., Mori, N., Ravi, R., and Bhujwalla, Z.M. (2003). Magnetic resonance molecular imaging of the HER-2/neu receptor. Cancer Res 63, 2723—27.[Abstract/Free Full Text]
• Biomarkers Definitions Working Group. (2001 ). Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Therapeutics 69, 89—95.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Blankenberg, F.G., Katsikis, P.D., Tait, J.F., Davis, R.E., Naumovski, L., Obtsuki, K., Kopiwoda, S., Abrams, M.J., and Strauss, H.E. (1999). Imaging of apoptosis (programmed cell death) with 99mTc annexinV. J Nucl Med 40, 184—91.[Abstract/Free Full Text]
• Cantor, C.R. (1999). Pharmacogenetics becomes pharmacogenomics: wake up and get ready. Molec Diag 4, 287—8.[CrossRef]
• Cantor, C.R. (2000). Biotechnology in the 21st century. Trends Biotechnol 18, 6—7.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Castera, L., Hartmann, D.J., Chapel, F., Guettier, C., Mall, F., Lons, T., Richardet, J.P., Grimbert, S., Morassi, O., Beaugrand, M., and Trinchet, J.C. (2000). Serum laminin and type VI collagen are accurate markers of histologically severe alcoholic hepatitis in patients with cirrhosis. J Hepatol 32, 412—8.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Cattley, R.C., and Radinsky, R.R. (2004). Cancer therapeutics: understanding the mechanism of action. Toxicol Pathol 32, this issue.
• Chandler, M., and Spain, M. (2003). Pitfalls to using small animals in preclinical testing are being eliminated. Preclinica 1, 245.
• Cooper, G.M. (1982). Cellular transforming genes. Science 218, 801—6.
• Davidson, J.F., Guo, H.H., and Loeb, L.A. (2002). Endogenous mutagenesis and cancer. Mutat Res 509, 17—21.[Web of Science][Medline] [Order article via Infotrieve]
• DeGeorge, J. (1998). Carcinogenicity testing: a new approach. In Proceeding of the 4th International Conference on Harmonization, Brussels, 1977 ( P. F. D'Arcy and D. W. G. Harron, eds.), pp. 261—3, Greystone Books, Antrim, N. Ireland.
• De La Vega, F.M., Dailey, D., Ziegle, J., Williams, J., Madden, D., and Gilbert, D.A. (2002). A new generation of pharmacogenomictools: a SNP linkage disequilibrium map, validated SNP assay resource, and high-throughput instrumentation for large-scale genetic studies. Biotechniques (June Suppl.), 48—50.
• Dobrovolsky, V.N., Casciano, D.A., and Heflich, R.H. (1999). Tk+/- mouse model for detecting in vivo mutation in an endogenous, autosomal gene. Mutat Res 423, 125—36.[Web of Science][Medline] [Order article via Infotrieve]
• Galloway, S.M. (1994). Chromosome aberrations induced in vitro: mechanisms, delayed expression, and intriguing questions. Environ Molec Mutagen 23(Suppl. 24), 44—53.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Gambhir, S.S., Barrio, J.R., Herschman, H.R., and Phelps, M.E. (1999). Assays for noninvasive imaging of reporter gene expression. Nucl Med Biol 26, 481—90.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• George, D.K., Ramm, G.A., Walker, N.I., Powell, L.W., and Crawford, D.H. (1999). Elevated serum type IV collagen: a sensitive indicator of the presence of cirrhosis in hemochromatosis. J Hepatol 31, 47—52.[Web of Science][Medline] [Order article via Infotrieve]
• Han, W.K., Bailly, V., Abichandani, R., Thadhani, R., and Bonventre, J.V. (2002). Kidney injury molecule-1 (KIM-1): a novel biomarker for human renal proximal tubule injury. Kidney Int 62, 237—44.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Heddle, J.A., Dean, S., Nohmi, T., Boerrigter, M., Casciano, D., Douglas, G.R., Glickman, B., Gorelick, N., Mirsalis, J., Martus, H.-J., Skopek, T., Thybaud, V., Tindall, K., and Yajima, N. (2000). In vivo transgenic mutation assays (Report of the Second International Workshop on Genotoxicity Testing, Washington, D.C., 1999). Environ Molec Mutagen 35, 253—9.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Hilliard, C.A., Armstrong, M.J., Bradt, C.I., Hill, R.B., Greenwood, S.K., and Galloway, S.M. (1998). Chromosome aberrations in vitro related to cytotoxicity of nonmutagenic chemicals and metabolic poisons. Environ Molec Muatagen 31, 316—26.[CrossRef]
• Holden, A.L. (2002). The SNP consortium: summary of a private consortium effort to develop an applied map of the human genome. Biotechniques (June Suppl.) 22—4, 26.
• Kilty, C., Doyle, S., Hassett, B., and Manning, F. (1998). Glutathione S-transferases as biomarkers of organ damage: Applications of rodent and canine GST enzyme immunoassays. Chem Biol Interact 111—112, 123—35.[CrossRef][Web of Science]
• Kirkland, D.J., and Müller, L. (2000). Interpretation of the biological relevance of genotoxicity test results: The importance of thresholds. Mutat Res 464, 137—47.[Web of Science][Medline] [Order article via Infotrieve]
• Lindon, J.C., Nicholson, J.K., Holmes, E., Antti, H., Bollard, M.E., Keun, H., Beckonert, O., Ebbels, T.M., Reily, M.D., Robertson, D., Stevens, G.J., Luke, P., Breau, A.P., Cantor, G.H., Bible, R.H., Neiderhauser, U., Senn, H., Schlotterbeck, G., Sidelmann, U.G., Laursen, S.M., Tymiak, A., Car, B.D., Lehman-McKeeman, L., Colet, J.-M., Loukaci, A., and Thomas, C. (2003). The role of metabonomics in toxicology and its evaluation by the COMET consortium. Toxicol Appl Pharmacol 187, 137—46.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• MacDonald, J., French, J.E., Gerson, R.J., Goodman, J., Inoue, T., Jacobs, A., Kasper, P., Keller, D., Lavin, A., Long, G., McCullough, B., Sistare, F.D., Storer, R., van der Laan, J.W. (2004). The utility of genetically-modified mouse assays for identifying human carcinogens—a basic understanding and path forward. Toxicol Sci 77, 188—194.[Abstract/Free Full Text]
• MacGregor, J.T. (2003). The future of regulatory toxicology: impact of the biotechnology revolution. Toxicol Sci 75, 236—48.[Abstract/Free Full Text]
• MacGregor, J.T., Casciano, D.A., and Müller, L. (2000). Strategies and testing methods for identifying mutagenic risks. Mutat Res 455, 3—21.[Web of Science][Medline] [Order article via Infotrieve]
• MacGregor, J.T., Farr, S., Tucker, J.D., Heddle, J.A., Tice, R.R., and Turteltaub, K.W. (1995). New molecular endpoints and methods for routine toxicity testing. Fund Appl Toxicol 26, 156—173.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Maisel, A.S., Krishnaswamy, P., Nowak, R.M., McCord, J., Hollander, J.E., Duc, P., Omland, T., Storrow, A.B., Abraham, W.T., Wu, A.H.B., Clopton, P., Steg, P.G., Westheim, A., Knudsen, C.W., Perez, A., Kazanegra, R., Herrmann, H.C., and McCullough, P.A. (2002). Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. New Eng J Med 347, 161—67.[Abstract/Free Full Text]
• McKinzie, P.B., Delongchamp, R.R., Heflich, R.H., and Parsons, B.L. (2001). Prospects for applying genotypic selection of somatic oncomutation to chemical risk assessment. Mutation Res 489, 47—78.[CrossRef][Medline] [Order article via Infotrieve]
• Mirsalis, J.C., Montforte, J.A., and Winegar, R.A. (1995). Transgenic animal models for detection of in vivo mutations. Ann Rev Pharmacol Toxicol 35, 145—64.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Mirsalis, J.C., Provost, G.S., Matthews, C.D., Hamner, R.T., Schindler-Horvat, J.E., O'Loughlin, K.G., MacGregor, J.T., and Short, J.M. (1993). Induction of hepatic mutations in lacI transgenic mice. Mutagenesis 8, 265—71.[Abstract/Free Full Text]
• Müller, L., and Kasper, P. (2000). Human biological relevance and the use of threshold arguments in regulatory genotoxicity assessment: experience with pharmaceuticals. Mutat Res 464, 19—34.[Web of Science][Medline] [Order article via Infotrieve]
• Nohmi, T., Katoh, M., Suzuki, H., Matsui, M., Yamada, M., Watanabe, M., Suzuki, M., Horiya, N., Ueda, O., Shibuya, T., Ikeda, H., and Sofuni, T. (1996). A new transgenic mouse mutagenesis test system using Spi- and 6-thioguanine selections. Environ Molec Mutagen 28, 465—70.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Pearson, T.A., Mensah, G.A., Alexander, R.W., Anderson, J.L., Cannon, R.O. 3rd, Criqui, M., Fadl, Y.Y., Fortmann, S.P., Hong, Y., Meyers, G.L., Rifai, N., Smith, S.C. Jr., Taubert, K., Tracy, R.P., Vinicor, F., Centers for Disease Control and Prevention, American Heart Association (2003). Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 107, 499—511.[Free Full Text]
• Petricoin, E.F., Ardekani, A.M., Hitt, B.A., Levine, P.J., Fusaro, V.A., Steinberg, S.M., Mills, G.B., Simone, C., Fishman, D.A., Kohn, E.C., and Liotta, L.A. (2002). Use of proteomic patterns in serum to identify ovarian cancer. Lancet 359, 572—7.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Physician's Desk Reference. (2003). Gleevec, 2278—2282; Herceptin, 1399— 1402; Prolastin, 923—925; Antihemophilic factor, 914—919; Thomson PDR, Montvale, New Jersey.
• Radman, M., Jeggo, P., and Wagner, R. (1982). Chromosomal rearrangement and carcinogenesis. Mutat Res 98, 249—264.[Web of Science][Medline] [Order article via Infotrieve]
• Ridker, P.M., Rifai, N., Rose, L., Buring, J.E., and Cook, N.R. (2002). Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. New Eng J Med 347, 1557—65.[Abstract/Free Full Text]
• Robinson, D.E., and MacDonald, J.S. (2001). Background and framework for ILSI's collaborative evaluation program on alternative models for carcinogenicity assessment. International Life Sciences Institute. Toxicol Pathol 29 (Suppl.), 13—19.[Abstract/Free Full Text]
• Robinson, D.E., Pettit, S.D., and Morgan, D.G. (2003). Use of genomics in mechanism based risk assessment. In Toxicogenomics (T. Inoue and W. D. Pennie, eds.), pp. 194—203. Springer-Verlag, Tokyo.
• Roses, A.D. (2001). 2025: the practice of neurology—back from the future. Arch Neurol 58, 1766—7.[Free Full Text]
• Roses, A.D. (2002). Genome-based pharmacogenetics and the pharmaceutical industry. Nat Rev Drug Discov 1, 541—9.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Rosty, C., Christa, L., Kuzdzal, S., Baldwin, W.M., Zahurak, M.L., Carnot, F., Chan, D.W., Canto, M., Lillemore, K.D., Cameron, J.L., Yeo, C.J., Hruban, R.H., and Goggins, M. (2002). Identification ofhepatocarcinomaintestine-pancreas/pancreatitis-associatedprotein-Ias abiomarkerforpancreatic ductal adenocarcinoma by protein biochip technology. Cancer Res 62, 1868—75.[Abstract/Free Full Text]
• Shields, A.F., Mankoff, D.A., Link, J.M., Graham, M.M., Eary, J.F., Kozawa, S.M., Zheng, M., Lewellen, B., Lewellen, T.K., Grierson, J.R., and Krohn, K.A. (1998). Carbon-11-thymidine and FDG to measure therapy response. J Nucl Med 39, 1757—1762.[Abstract/Free Full Text]
• Stambrook, P.J., Shao, C., Stockelman, M., Bovin, G., Engel, S.J., and Tishfield, J.A. (1996). APRT: a versatile in vivo resident reporter of local mutation and loss of heterozygosity. Environ Molec Mutagen 28, 471—82.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Stumpf, M.P. (2002). Haplotype diversity and the block structure of linkage disequilibrium. Trends Genet 18, 226—8.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Thybaud, V., Dean, S., Nohmi, T., de Boer, J., Douglas, G.R., Glickman, B.W., Gorelick, N.J., Heddle, J.A., Heflich, R.H., Lambert, I., Martus, H.J., Mirsalis, J.C., Suzuki, T., and Yajima, N. (2003). In vivo transgenic mutation assays (Report of the Third International Workshop on Genotoxicity Testing, Plymouth, U.K., June 28-29, 2002). Mutat Res 540, 141—51.[Web of Science][Medline] [Order article via Infotrieve]
• Van de Vijer, M.J., He, Y.D., van't Veer, L.J., Dai, H., Hart, A.A.M., Voskuil, D.W., Schreiber, G.J., Peterse, J.L., Roberts, C., Marton, M.J., Parrish, M., Atsma, D., Witteveen, A., Glas, A., Delahaye, L., van der Velde, T., Bartelink, H., Rodenhuis, S., Rutgers, E.T., Friend, S.H., and Bernards, R. (2002). A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347, 1999—2009.[Abstract/Free Full Text]
• Vasella, D., and Slater, R. (2003). Magic Cancer Bullet: How a Tiny Orange Pill is Rewriting Medical History. HarperCollins Publishers, New York.
• Venter, J.C., Adams, M.D., Myers, E.W., Li, P.W., Mural, R.J., Sutton, G.G., Smith, H.O., Yandell, M., Evans, C.A., Holt, R.A., et al. (2001). The sequence of the human genome. Science 291, 1304—51.[Abstract/Free Full Text]
• Wallace, K.B., Hausner, E., Herman, E., Holt, G.D., MacGregor, J.T., Metz, A.L., Murphy, E., Rosenblum, I.Y., Sistare, F.D., and York, M.J. (in press). Serum troponins as biomarkers of drug-induced cardiac toxicity. Toxicol Pathol 32, 106—121.
• Weber, W.A., Schwaiger, M., and Avril, N. (2000). Quantitative assessment of tumor metabolism using FDG-PET imaging. J Nucl Med 27, 683— 687.
• Wijhoven, S.W., van Sloun, P.P., Kool, H.J., Weeda, G., Slater, R., Lohman, P.H., van Zeeland, A.A., and Vrieling, H. (1998). Carcinogen-induced loss of heterozygosity at the Aprt locus of somatic cells in the mouse. Proc Natl Acad Sci USA 95, 13759—64.[Abstract/Free Full Text]
• Wooster, R., and Webster, B.L. (2003). Breast and ovarian cancer. N Engl J Med 348, 2339—47.[Free Full Text]
• Yang, B. (2003). Magic cancer bullet. Discov Med 3, 16—19.

Toxicologic Pathology, Vol. 32, No. 1 suppl, 99-105 (2004)
DOI: 10.1080/01926230490425067


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This Article Abstract Free Full Text (Free PDF) Free Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Macgregor, J. T. Search for Related Content PubMed PubMed Citation Articles by Macgregor, J. T. Pubmed/NCBI databases Medline Plus Health Information Cancer Cancer Chemotherapy Social Bookmarking                         What's this?